Miller, Miles , PhD
Miles Miller received his A.B. in Chemistry from Princeton University, and his Ph.D. in Biological Engineering from the Massachusetts Institute of Technology (Advisors: Douglas Lauffenburger and Linda Griffith). He trained as a NIH postdoctoral fellow under Dr. Ralph Weissleder at MGH. He specializes in parsing mechanisms of cell signaling and drug action from a quantitative network-level perspective, with training in computational modeling, imaging, nanotechnology, cell signaling biology, and drug delivery.
Imaging of anticancer drug action in single cells
It’s what’s inside that counts for nanoparticle vaccines
Less is more for anticancer therapy combinations
Driver mutations take the wheel in invasive yet nonmalignant disease.
Radiation therapy primes tumors for nanotherapeutic delivery via macrophage-mediated vascular bursts
In vivo imaging reveals a tumor-associated macrophage–mediated resistance pathway in anti–PD-1 therapy
Nanoparticles improve economic mileage for CARs.
Richer data with personalized GEMs.
Nano-palladium is a cellular catalyst for in vivo chemistry
Heterogeneity of macrophage infiltration and therapeutic response in lung carcinoma revealed by 3D organ imaging.
Near infrared imaging of Mer tyrosine kinase (MERTK) using MERi-SiR reveals tumor associated macrophage uptake in metastatic disease
Profiling of metalloprotease activities in cerebrospinal fluids of patients with neoplastic meningitis.
Simultaneous Detection of Metalloprotease Activities in Complex Biological Samples Using the PrAMA (Proteolytic Activity Matrix Assay) Method.
Modification of proteolytic activity matrix analysis (PrAMA) to measure ADAM10 and ADAM17 sheddase activities in cell and tissue lysates.
Prediction of Anti-cancer Nanotherapy Efficacy by Imaging